Clinical trials

Our clinical trial history
spanning the last 20 years

Here you’ll find a comprehensive overview and links to detailed information on our past studies, including their objectives, methods and results. These trials represent milestone, sometimes breakthrough, steps in our understanding of tau aggregation inhibitors and their potential in treating neurodegenerative diseases.

Explore this timeline for insights into the progression and depth of our scientific efforts.

TauRx recently completed its latest Phase III clinical trial, named LUCIDITY. In collaboration with neurologists and clinical research centres in North America and Europe, this trial aimed to prove that our main drug works, following earlier tests that showed it had measurable effects even in small amounts. The trial studied the effect of the drug on patients with mild cognitive impairment due to Alzheimer’s, and mild to moderate Alzheimer’s.

The trial used common tests to check cognitive skills and daily functioning, along with brain scans and blood tests. These helped us measure how well our drug might slow down Alzheimer’s disease, and included an open-label phase during which all participants received the drug. Patients completing the full trial were eligible for continued use of the drug under an Expanded Access Programme.

TauRx has completed Phase III trials related to Alzheimer’s disease and the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).